XML 40 R25.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2018

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule of intangible assets

The following tables sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of June 30, 2018 and December 31, 2017:

		June 30, 2018
		Gross Carrying Amount				Accumulated Amortization				Net Amount				Weighted- Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
OPERA^®software patent		$	31,951			$	(9,486	)		$	22,465				11.25
Development costs of corporate website			91,743				(91,743	)			—				n/a
Approved hormone therapy drug candidate patents			1,662,562				(216,934	)			1,445,628				14.5
Hormone therapy drug candidate patents (pending)			1,769,681				—				1,769,681				n/a
Non-amortizable intangible assets:
Multiple trademarks			250,627				—				250,627				indefinite
Total		$	3,806,564			$	(318,163	)		$	3,488,401

		December 31, 2017
		Gross Carrying Amount				Accumulated Amortization				Net Amount				Weighted- Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
OPERA^®software patent		$	31,951			$	(8,487	)		$	23,464				11.75
Development costs of corporate website			91,743				(91,743	)			—				n/a
Approved hormone therapy drug candidate patents			1,293,614				(171,911	)			1,121,703				15
Hormone therapy drug candidate patents (pending)			1,721,305				—				1,721,305				n/a
Non-amortizable intangible assets:
Multiple trademarks			233,275				—				233,275				indefinite
Total		$	3,371,888			$	(272,141	)		$	3,099,747

Schedule of estimated amortization expense

Estimated amortization expense for the next five years for the patent cost currently being amortized is as follows:

Year Ending December 31,				Estimated Amortization
	2018(6 months)			$	49,652
	2019			$	99,304
	2020			$	99,304
	2021			$	99,304
	2022			$	99,304
	Thereafter			$	1,021,225